The second Life Sciences Sector Deal will support healthcare innovation and back businesses to create high-paid, high-quality jobs as part of the government’s modern Industrial Strategy.

• life-saving early disease detection technology to be developed by new partnership between government and industry using artificial intelligence (AI) to develop the next generation of treatments, including a first-of-its-kind national health programme
• the second Life Sciences Sector Deal, with industry investment from 10 companies, will support healthcare innovation and back businesses to create high-paid, high-quality jobs as part of the government’s modern Industrial Strategy
• the deal signals a vote of confidence in UK industry, with global biopharmaceutical company UCB investing around £1 billion in research and development, including in a new state-of-the-art facility

In Manchester, healthcare company Roche, will invest £20 million investment over three years in a precision cancer research partnership with the Christie NHS Foundation Trust in Manchester. This will use cutting-edge genomic technology and big data to accelerate the next generation of digital clinical trials for rare cancers, making the UK a leading global hub for rare cancer trials, potentially benefiting nearly 5,000 patients annually.

Commenting on the news, Prof Ben Bridgewater, Chief Executive of Health Innovation Manchester, said: “The news further cements Manchester’s position as being at the leading edge of precision healthcare and is fast becoming a global life sciences cluster.  This is further enhanced by devolution and our strong expertise in tech, digital and data sciences.”

Read the full release on the Gov.uk website

The AHSN Network welcomes the government’s Life Science’s Sector Deal 2, announced this week by Health Secretary Matt Hancock and Businesses Secretary Greg Clark.

This second Life Sciences Sector Deal will support healthcare innovation and back businesses to create high-paid, high-quality jobs as part of the government’s Industrial Strategy.

Strong progress has already been made since publication of the first Life Sciences Sector Deal published in December 2017. The new deal cites the strengthened role of the AHSNs in improving NHS access to new technologies. The AHSNs are working with industry and local NHS partners to: understand local health and care needs; support system navigation; provide access to testing; and support the adoption and spread of products in the NHS. This has underpinned AHSN engagement with 1,173 companies so far this financial year, leading to 86 long term strategic partnerships for companies with the NHS.

Another significant achievement in the last year has been the implementation of the Accelerated Access Review with government, industry, the NHS and its partners working together to put NHS patients at the forefront of the latest advances in healthcare. A key component of this going forward is the new programme of work with a much-enhanced and strengthened Accelerated Access Collaborative with a mandate to oversee the innovation landscape for all types of technology.

The role of AHSNs is recognised in the Life Science’s Sector Deal 2 as central to building a stronger innovation ecosystem and as a crucial partner in the Accelerated Access Collaborative for the delivery of a consistent, high quality offer to innovators and the health system across the country.

Wound care sector deal

The Life Science’s Sector Deal 2 also gives its backing to the wound care industry through its support for the development and uptake of digital clinical decision-making tools.

The wound care sector deal involves industry, the AHSN Network and the NHS working together, with government commitments to improve innovation adoption, to reduce variation and improve patient outcomes in wound care treatment.

The wound care deal is an important step for the health technology sector, with the announcement well-placed to provide the framework for future agreements.

Commenting on the news, Chair of the AHSN Network, Seamus O’Neill said: “The AHSN Network will be working with the NHS and the wound care industry as part of the Office for Life Sciences’ Industrial Strategy. The AHSN has expertise in the Quality Improvement initiatives required to deliver sustained improvements in outcomes across the NHS. Partnership with industry colleagues will help us to do more, faster. The consortium will be a vehicle for exploring how the use of digital clinical decision support tools can reduce variation in wound care, maximise the impact of resources and improve patient outcomes.”

Una Adderley, National Wound Care Strategy Programme Director, AHSN Network, added: “We are delighted that the Life Sciences Sector Deal 2 has included wound care as a focus. Industry and innovation are important in the emerging National Wound Care Strategy Programme and we welcome this opportunity for closer collaborative working to improve care for patients with wounds.”

ABHI CEO Peter Ellingworth commented: “I am pleased to see this significant backing of our sector. HealthTech products and services deliver vital improvements to patient care and enable a more efficient health care system. As such, we are working with Government to ensure that the agreement encapsulates a broad range of wound care and digital companies, whilst exploring how this approach to collaborative working can be applied to other areas of our industry. These partnerships will deliver value across the whole health system, and NHS procurement decisions must recognise that, rather than simply focusing on achieving lowest price.”